Postantibiotic effects of anti-tuberculosis drugs on mycobacterium tuberculosis. by Au-Yeang, Carrie (Ka Wai) & Chinese University of Hong Kong Graduate School. Division of Microbiology.
The Chinese University ofHong Kong 
Postantibiotic Effects of Anti-tuberculosis Drugs 
on Mycobacterium tuberculosis 
(0'^ 
A Thesis Submitted to the Division ofMicrobiology， 
Faculty of Graduate Studies, for Partial Fulfilment of the 







Copyright © The Chinese University ofHong Kong 
f i i 
U U ： 
//^^'---^^^ 
A..^大\\八 
L / M ^ A i i i _ ^ _ x A 
- 二 广 — ^ % \ 
m 0 ] m m s � 
l,9rV -_~-JsJ 
^ \ i>'”!’'，'，' 瑪 
W L:。,： •:. : ” � � S > ^ -
\ : � i > - 一 一 - < r W \ 
X> <-'y ‘ ‘ •: •• r-. ,'. t ‘ , ..\ ^ ^ •： 



























Postantibiotic effects (PAEs) and bactericidal activities expressed in killing indices 
(KIs) in vitro and ex vivo of six antimicrobial agents including rifampicin (R), 
isoniazid (H), amikacin and three quinolone compounds of ofloxacin (0), 
levofloxacin (L) and sparfloxacin (S), used alone and in combinations amongst 
themselves or with pyrazinamide (Z) and ethambutol (M) were studied against a 
standard strain and two clinical isolates of Mycobacterium tuberculosis. A 
radiometric culture medium with the Bactec 460 instrument was used for the study of 
PAE after verification by the classical viable count method. Results have indicated 
that PAEs generated by measurement of cumulative growth index at TlOO by the 
Bactec method were more consistent than the viable count method although both 
methods produced similar figures. Among the six drugs used alone, rifampicin 
produced the longest PAE (58.1 h) in vitro against the standard strain of M. 
tuberculosis H37Rv , followed by amikacin (19.2 h) and isoniazid (11.5 h), while the 
quinolones gave negligible PAEs, if any. Results of PAEs ex vivo of these drugs 
used alone against H37Rv phagocytised by THP-1 differentiated macrophages 
revealed that longer PAEs were observed for rifampicin (72.7 h) and ofloxacin (9.7 
h) probably due to the higher intracellular concentrations, while amikacin and the 
other quinolones gave negligible PAEs. When combinations of antituberculous drugs 
were tested for their PAEs ex vivo, it was found that the combination of HRZM gave 
the longest PAE of 119.1 h, followed by HRA (97.2 h), HRZ (96.7 h), and ORA 
(95.0 h), while the combination of ORM gave the shortest PAE of 17.9 h. Results 
from the bactericidal killing studies revealed significant killings of the 
mycobacterium, especially for rifampicin, isoniazid and the combinations tested. 
Although quinolones produced negligible PAEs in vitro and ex vivo, the use of 
ofloxacin in combination with other antituberculous drugs produced significant PAEs 
and bactericidal effects ex vivo which would allow this compound to be used as a 
reserve dmg for antituberculosis therapy. It was concluded that the PAEs and KIs 
obtained from in vitro and ex vivo studies of the selected antituberculous drugs and 
their combinations could provide useful laboratory data which would support the use 
of the present antituberculous chemotherapeutic regimens. 
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VIL Introduction 
Mycobacterium tuberculosis like no other disease has taken its toll of human life 
over the millennia and has spread literally world-wide, it remains a major clinical 
issue with about one-third of the world's population being infected (Kochi 1991). 
The resurgence of tuberculosis together with a rise in the number of cases of drug-
resistant isolates can, in part, be attributed to the epidemic of human 
immunodeficiency virus (HIV) infection (Brudney and Dobkin 1992) have 
heightened the urgency in search of new antituberculous agents as well as more 
effective treatment. 
There are numerous effective regimens with different dmg combinations for treating 
pulmonary tuberculosis. The current standard, which has evolved over many years 
and is based on dozens of clinical trials, for uncomplicated susceptible tuberculosis is 
a 6-month regimen consisting of 2 months of isoniazid, rifampicin and pyrazinamide 
followed by 4 months of isoniazid and rifampicin taken twice or thrice weekly 
(American Thoracic Society 1994). In the case of multiple drug resistant 
tuberculosis or in the presence of hepatic dysfuntion, which is more common among 
elderly patients who in tum are most at risk from tuberculosis apart from HIV 
infected individuals (Davies 1994; Yew and Chau 1997), there are no specific 
guidelines for regimens other than that it should be tailored based on dmg 
susceptibility results. Second-line drugs, which are in general less effective but more 
toxic, such as ethionamide, cycloserine, capreomycin and kanamycin have to be 
used. However, newer drugs such as amikacin and the fluoroquinolones have shown 
good antituberculous activities, in particular, ofloxacin has shown distinct clinical 
efficacy (Yew et al. 1990; Yew et al. 1992). 
In the design of a rational dosage regimen, parameters such as early bactericidal 
activity, postantibiotic effect (PAE) and sterilising activity should be considered in 
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addition to the in vitro minimum inhibitory and bactericidal concentrations. PAE 
which may allow for more widely spaced dosing of antimicrobials without the loss of 
efficacy would not only lower the cost of therapy and the risk of toxicity but may 
also encourage compliance as well as ensuring the efficacy of subsequent doses 
(Meng etal. 1994). 
The objective of this study is to elucidate the PAE and KI in vitro and ex vivo of 
antituberculous drugs used alone and in combinations to provide laboratory support 
for clinical therapeutic regimens of M. tuberculosis. 
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VIII. Literature Review 
A. Mycobacterium tuberculosis Infections - clinical importance 
Mycobacterium tuberculosis is a pathogen, which can cause pulmonary and 
extrapulmonary infections, that had invaded humans as early as the prehistoric times 
(Sager et aL 1972; Zimmerman 1979), is causing higher morbidity and mortality 
rates than any other infections in the world (Dolin et aL 1994). The disease became a 
major public health problem during the Industrial Revolution (Holmberg 1990), and 
since then the incidence has decreased largely due to improved living standards and 
the availability of effective chemotherapy. It was noted in the last decade that there 
has been a resurgence of tuberculosis all over the world (Reider et al. 1989; Centers 
for Disease Control 1993b; Raviglione et al. 1995), with the emergence of multiple 
drug resistant strains (MDR-TB) being resistant to isoniazid and rifampicin or more 
antituberculous drugs especially found in patients with the acquired 
immunodeficiency syndrome (Fischi et aL 1992). It is obvious that the control of 
tuberculosis has never been fully resolved and remained as an important clinical 
problem for clinicians, health care workers as well as researchers. 
B. Treatment of M. tuberculosis Infections - the past & present 
The first phase in the development of the chemotherapy of tuberculosis started in the 
late 1940s with the introduction of several potent antibacterial drugs, streptomycin 
first and then p-aminosalicylic acid, isoniazid, ethionamide and pyrazinamide, as 
well as several minor drugs (Mitchison 1992). The main emphasis was on the use of 
double-drug combinations, supplemented later by an initial triple-drug intensive 
phase, to prevent the emergence of drug-resistant tubercle bacilli. In the late 1950s, 
the attention tumed to methods for improving compliance during periods of therapy 
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that often lasted over a year. Intermittent regimens were developed which facilitated 
fully supervised drug administration, as well as reducing drug costs and toxicity. 
The introduction of short-course regimens in the early 1970s allowed treatment 
period to be reduced drastically (East African/ British Medical Research Councils 
1974). Current interest is turning to the sterilising activity of drugs which would 
eventually determine the duration of treatment. The time it takes to kill the last 
surviving organisms is termed the 'sterilising activity' of the drug. It seems likely 
that the last few bacilli to be killed are part of a slowly metabolising population 
which was present at the start of treatment. The ability to kill these last slowly 
metabolising, persisting bacilli determines how effective the dmg will be in 
shortening the period of chemotherapy (Mitchison 1992). 
Current treatment recommended for tuberculosis employs a combination of isoniazid, 
rifampicin, and pyrazinamide for 2 months followed by isoniazid and rifampicin for 
an additional 4 months as the standard 6-month regimen for compliant patients with a 
fully susceptible M tuberculosis isolate (Wolinsky 1993; American Thoracic Society 
1994). At least two additional active agents should be added to failing treatment 
regimens in any patients with tuberculosis (Iseman 1993; Johnson and Chaisson 
1993-94; Ellner 1995). A 9-month regimen should be used with patients who cannot 
tolerate pyrazinamide. In the absence of susceptibility results, patients with 
suspected or proven MDR-TB should be treated with amikacin, a quinolone, 
ethambutol, pyrazinamide, and perhaps a fifth drug, e.g., rifampicin, rifabutin, 
isoniazid, cycloserine, or ethionamide (Wolinsky 1993). 
Combination of drugs are used primarily to prevent the emergence of resistance; 
however, there have been evidences to indicate that first-line agents may act in a 
synergistic manner. This synergism may reflect combined effects on tubercle bacilli 
but most likely also reflects the fact that different drugs may act on tubercle bacilli in 
different physiologic states. M. tuberculosis is likely to exist in the tissue under 
different physiologic conditions (Inderlied and Nash 1996): (a) rapidly growing cells 
in the aerobic and neutral-pH environment of the pulmonary cavity; (b) slowly 
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growing cells in the oxygen-depleted and low-pH environment of the caseous 
lesions, where the burden of tubercle bacilli is highest; (c) cells within macrophages; 
and (d) dormant tubercle bacilli, which are the most intractable to treatment and the 
likely source of reactivation. Mitchison (Mitchison 1992) named this phenomenon 
as a "special populations" hypothesis. According to his hypothesis, isoniazid, 
rifampicin, and streptomycin are most active against the relatively rapidly dividing 
bacilli, rifampicin is likely to also be active against bacilli that grow in spurts, and 
pyrazinamide is active against bacilli in the acidic milieu of caseous lesions and in 
acidified vacuoles of macrophages. At present there are no agents that are known to 
be active against dormant bacilli; however, Wayne and Sramek (Wayne and Sramek 
1994) recently provided evidence that metronidazole is active against dormant 
bacilli, based on the assumption that these bacilli exist under largely anaerobic 
conditions. 
C. Laboratory Support for Treatment ofTuberculosis 
Laboratory support for the treatment of tuberculosis included the studies of drug 
susceptibility testing, pharmacokinetics and pharmacodynamics of the drugs being 
used, and the newly developed area of early bactericidal activity (EBA) and 
postantibiotic effect (PAE) of the drugs. 
Susceptibility testing in vitro of antituberculous drugs can be performed by several 
methods, including the absolute concentration method, the resistance ratio method, 
the proportion method, and the comparatively recent radiometric method (Inderlied 
and Nash 1996). All of these methods, together with pharmacokinetic and 
pharmacodynamic data of the drugs, can provide guidelines for the choice of the 
antituberculous drugs for chemotherapy against tuberculosis. 
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In addition to the use of susceptibility results and pharmacokinetic data, early 
bactericidal activities of drugs have been introduced. When the activity of rifabutin 
and rifampicin against rapidly growing, extracellular Mycobacterium tuberculosis in 
cavity walls was measured by counting colony-forming units (CFU) in the sputum of 
patients with newly diagnosed, severe pulmonary tuberculosis during the first 2 days 
of chemotherapy, the fall in counts, (logio CFU/mL sputum/day), was termed the 
early bactericidal activity (EBA) (Sirgel et al. 1993). Studies on the EBA of 
ethambutol, pyrazinamide and rifater have also been reported (Botha et al. 1996), and 
it was suggested that the methodology of studying EBA may be valuable in the rapid 
evaluation of the bactericidal activity of new antituberculosis agents. The 
determination of EBA could also be used as a method of comparing the potency of 
different dose sizes of agents of the same type in human lesions before embarking on 
a conventional clinical trial. 
Other than the applications of susceptibility results, pharmacokinetic and 
pharmacodynamic data plus the EBA evaluation of the antituberculous drugs, the 
studies of PAE may also be significant guidelines for setting up chemotherapeutic 
regimens. 
D. The Postantibiotic Effects (PAE) 
1. The Postantibiotic Effects 
Delayed regrowth of bacteria following removal of antimicrobial agents was first 
described by Bigger in 1944 (Bigger 1944) who noted delayed development in 
turbidity after adding penicillinase to cultures of staphylococci and streptococci 
previously exposed to penicillin G. Two years later Parker and Marsh (Parker and 
Marsh 1946) and then Parker and Luse (Parker and Luse 1948) demonstrated that 
strains of Staphylococcus aureus exposed to benzylpenicillin for 5 to 30 minutes did 
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not resume normal growth when transferred to drug-free medium for approximately 1 
to 3 hours. This phenomenon of persistent suppression of bacterial growth was 
termed the postantibiotic effect (PAE) (McDonald et aL 1977; Bundtzen et al. 1981). 
Since the 1970s, a vast amount of studies have been conducted for a variety of drug-
organism combinations in vitro and most of them showed some evidence of a PAE. 
The major exception was some p_lactam drugs had insignificant or negative PAEs 
against gram negative bacilli (Bundtzen et aL 1981; Gudmundsson et aL 1986; 
Hanberger et aL 1990b). Postantibiotic effects have also been demonstrated with 
studies in animal models and that the PAE in vivo is generally more prolonged than it 
is in vitro (Vogelman et aL 1988b; Fantin et aL 1991; Craig 1993a). 
2. Determination ofPAE 
A variety of methods have been used to demonstrate and quantify the postantibiotic 
effect in vitro. The most widely used method, and often the method to compare with 
when considering novel technique, is by limited exposure of organism to an 
antimicrobial agent and after removal of dmg, monitor the bacterial regrowth by 
serial viability counts (Craig and Gudmundsson 1991; Craig and Gudmundsson 
1996). Rapid removal of antimicrobials have been achieved through dilution of 
bacteria into drug-free medium (Davidson et aL 1991; Tsui et al. 1993; Turnidge et 
aL 1994), filtration through membrane filters (Holbrook et aL 1989; Lorian et aL 
1989), enzymatic inactivation of dmg (Eagle 1949; Bundtzen et aL 1981; den 
Hollander et aL 1996) and repeated washing (Parker and Luse 1948; McDonald et aL 
1977; Bermudez et aL 1992). In vitro kinetic models which simulate in vivo 
fluctuating drug levels have also been used (Zhanel and Craig 1992; Maggilol et al 
1994). 
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Other methods have been developed to quantify the PAE in bacterial cultures. For 
example measurement of optical density (Baquero et aL 1986; Meng et al. 1991; 
Lowdin et aL 1993), bioluminescence assay of intracellular ATP (Isaksson et aL 
1988; Hanberger et al. 1990a; Hanberger et aL 1995), electrical impedance (Baquero 
et aL 1986; MacKenzie et aL 1994; Majcherczyk et aL 1994), and conductance 
measurement of bacterial growth (Gould et aL 1989; Jason et aL 1994). Bacterial 
morphological changes (Lorian et aL 1989; Lorian et aL 1995), CO2 generation by 
bacterial metabolism and the E-test technology (Bolmstrom 1994) have also been 
used to determine PAE. 
In most in vitro studies, the growth kinetics of the exposed and unexposed control 
were compared and in order to relate similar experiments on different days as well as 
to compare different methodologies, the formula 'PAE = T - C, was developed 
(McDonald et aL 1977; Bundtzen et aL 1981; Craig and Gudmundsson 1986 ). 'T' is 
the time required for the bacterial counts of the exposed cultures to increase 1 logio 
above the counts observed immediately after drug removal and 'C' is the 
corresponding time required for the counts of the untreated cultures. 
3. In Vivo Models for the Determination ofPAE 
PAE in vivo is defined as the difference in time needed for the organisms in the 
treated animals to grow 1 logio as compared with controls after serum drug 
concentrations have fallen below the MIC. Several models have been developed for 
the study of PAE in vivo, including the mouse thigh infection model (Gudmundsson 
et aL 1993; Majcherczyk et aL 1994), the mouse pneumonia model (Craig et aL 
1991; Leggett et aL 1992), the infected subcutaneous threads in mice model 
(Renneberg and Walder 1989), the rabbit meningitis model (Sande et aL 1981; 
Tauber et aL 1984) , the rabbit infected tissue cages model (Odenholt et aL 1988; 
Bergholm and Dornbusch 1990), and the rats endocarditis models (Ingerman et aL 
1986; Hessen et aL 1989). All these models made use of treatments for induced 
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infections in animals to elucidate the PAE based on the delayed of growth of the 
pathogens after drug administrations, but they have not been applied to examine in 
vivo PAE concerning tuberculosis. 
4. Factors Affecting PAE 
Duration, and even presence or absence ofPAE in vitro include the type of organism, 
the mode of action and concentration of antibiotics, the duration of exposure to the 
antibiotics, the size of inoculum and the type and pH of the medium (Craig and 
Gudmundsson 1991). It is anticipated that more factors, including unknown factors, 
will be involved in the determination of PAE when an in vivo model is used since 
interactions between the pathogens and the hosts are more difficult to be controlled. 
An ex vivo model using cells generating from cell-lines would provide a 
comparatively simpler model than using whole animals although one still cannot 
exclude unknown factors provided by the cells upon infection. 
5. The Postantibiotic Effect Related Phenomena 
The concept of PAE should not only be considered as prolonged suppression of 
bacterial growth but also as a potential inducer of decreased microbial virulence 
which may directly or indirectly influence the host-parasite relationship (Shibl et al. 
1995). PAEs are multiple, including delayed recovery of proteins, prolonged 
changes in cell morphology, metabolic alteration, modifications of generation times, 
susceptibility to phagocytosis and altered susceptibility to antibiotics after re-
exposure. Many of these effects are probably related (MacKenzie and Gould 1993). 
Altered susceptibility to polymorphonuclear (PMN) cells during the PAE phase is 
known as the post antibiotic leukocyte effect (PALE) (Pruul and McDonald 1990; 
Bayer et al. 1991). PALE was found to be both strain- and drug-dependent. Protein 
synthesis inhibitors such as aminoglycosides and macrolides were shown to display a 
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greater PALE in Escherichia coli than the cell-wall acting p-lactams (McDonald et 
al. 1983). S. pneumoniae exposed to roxithromycin increased its opsonization 
susceptibility and phagocytosis but the same was not found in Streptococcus 
pyogenes (Gemmell and McLeod 1992). Enhanced susceptibility of Streptococci to 
the killing of human PMNs after exposure to erythromycin and azithromycin was 
noted beyond the PAE phase (Ramadan et al. 1995). A short exposure to 
vancomycin increased the susceptibility of Enterococcus faecalis to PMNs (Bayer 
and Tu 1990). Short exposure of Pseudomonas aeruginosa to supra-MICs of 
amikacin increased killing by PMNs even in absence of opsonization (Bayer et al. 
1991). 
Shibl (Shibl et al. 1995) suggested that changes in bacteria-PMN interactions could 
be due to antibiotic induced modifications of the cell surface which enhanced 
intracellular killing. Supporting this rationale are the morphological changes 
observed in bacteria in relation to PAE (Lorian et al. 1989), E.coli after exposure to 
ampicillin and ciprofloxacin was observed to form rapid filamentation. It was also 
shown that dicloxacillin increased the number of cross-walls and rifampicin 
produced cell wall thickening in S. aureus during PAE phase while intracellular 
electron dense aggregates were seen in P. aeruginosa after exposure to imipenem 
(Gottfredsson et al. 1993). Other morphological alterations, including enlargements 
of organism and forming of spheroplasts were observed (Watanabe et al. 1992; 
Gudmundsson et al. 1986). 
Adherence of treated bacteria is also altered during the PAE phase. Bacterial 
adherence is influenced by the net surface charge and/or specific binding 
arrangement by host factors and by strain variation (Shibl et aL 1995). During the 
PAE phase, the residual antibiotic may cause leakage of bacterial adhesins 1 (p-
lactam) or may suppress the formation and expression of adhesins (Lorian 1991). E. 
coli treated with subinhibitory concentrations of ampicillin attach less well compared 
to untreated control bacteria (Sandberg et aL 1979). It has also been found that cell 
surface charge of Streptococci to hydrocarbon is altered after exposure to macrolides 
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(Shibl et al. 1994; Ramadan et al. 1995). The decrease in hydrophobicity was 
unrelated to inhibition of growth and may be explained on the basis that macrolides 
inhibit adhesin synthesis in Streptococci (Shibl 1985). Finally, total cellular 
metabolism of P. aeruginosa measured by release of charged metabolites, remained 
inhibited after exposure to antibiotic, even though cells were multiplying normally on 
agar plates (Majcherczyk et al. 1994). 
A broader definition of the PAE was proposed by Bergeron (Bergeron 1992) who 
defined PAE as "the persistence of an antibiotic effect for a variable period after 
cessation of exposure of micro-organisms to an effective antibiotic". This definition 
acknowledges the fact that the activities of an antibiotic may be broader than simply 
inhibiting growth and that additional effects may be of clinical significance 
(Maj cherczyk 1996). 
The current simple definition of the PAE is basically flawed since it assumes that the 
cell population is homogeneous and that recovery of each individual cell follows an 
identical time-course. However, it has been shown that the cell size distribution of a 
bacterial population was significantly reduced, even though viable counts of the 
culture were increasing at the normal rate (Majcherczyk et al. 1994). Such 
physiologically altered populations are likely to differ in their susceptibility to 
phagocytosis, and in their ability to produce toxins and other pathogenic properties 
(Majcherczyk 1996). 
It is thus clear that the physiology of bacterial cells (cell size, adherence, 
susceptibility to killing by host defences) is greatly altered following exposure to 
antibiotics and that these parameters take a longer time to recover than the ability to 
form a visible biomass on an agar plate (Majcherczyk 1996). 
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6. Mechanism ofPAE 
The mechanisms by which PAE occur have not been fully understood. Possible 
mechanisms include non-lethal damage induced by the antimicrobial agent and drug 
persistence at the binding site (Craig and Gudmundsson 1996). 
Studies on bacterial metabolism during PAE period have been limited but might 
provide insight into the nature of the PAE (Gottfredsson et aL 1995). DNA synthesis 
in bacteria during the PAE period after a 1-h exposure of organisms in the 
logarithmic growth phase to various antibiotics has been examined by measuring the 
rate of [3H]thymidine incorporation in S. aureus and E. coli and [3H]adenine 
incorporation in P. aeruginosa. DNA synthesis in S. aureus was found to be 
suppressed during the PAE phase with vancomycin, dicloxacillin, and rifampicin, in 
E. coli with rifampicin, and in P. aeruginosa after exposure to tobramycin. 
Conversely, DNA synthesis was relatively enhanced in the gram-negative bacilli 
after exposure to imipenem and in all three species after exposure to ciprofloxacin. 
However, DNA synthesis in E. coli was only minimally affected after exposure to 
tobramycin and gentamicin. The differences in DNA synthesis observed after 
exposure to various antimicrobial agents suggest multiple mechanisms for the PAE 
phenomenon observed and further work would be needed to elucidate the 
mechanism. 
7. Clinical Significance ofPAE 
During the past two decades, studies on postantibiotic effects have attracted new 
interest. The significance of postantibiotic effect (PAE), as a pharmacodynamic 
parameter has been increasingly considered in the design of dosing regimens (Craig 
1993a; Kikuchi and Shimizu 1992), and quantifying PAE was recommended in the 
published guidelines of the Infectious Diseases Society of America for preclinical 
evaluation of all new antimicrobials (Beam et aL 1992). 
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Very often, there seems to be little scientific basis for the frequency with which many 
antibiotics are administered. Antimicrobial combinations are widely used, however, 
dosing schedules are usually based on pharmacological profiles of individual drugs 
used alone. PAE which may in part explain the observation that some antimicrobial 
agents continue to suppress bacterial growth despite their presence is subinhibitory or 
undetectable in serum (Ellis et aL 1995), may not only allow for more widely spaced 
dosing of antibiotics without the loss of efficacy and more cost-effective but may 
also encourage compliance. 
PAE determined in vitro represent a very artificial way of looking at its presence 
since, in vivo, the drug concentrations at the site of infection are always fluctuating 
and are further affected by the bacterial environment such as pH, dmg inactivation 
and binding to proteins. On the other hand, we are probably underestimating this 
significance since, in vivo, high drug concentrations are always followed by sub-
MICs which most probably add to the PAE. 
The existence of a prolonged regrowth of certain antimycobacterial agents against M. 
tuberculosis has been used as support for wide dose intervals and intermittent drug 
dosing in the treatment of tuberculosis. 
It has been proposed that the optimum dosing interval could be calculated as the sum 
of the time that the serum drug concentration exceeded the MIC plus the duration of 
PAE (Turnidge 1990). Therefore, the optimum dosing interval for a certain drug-
organism combination may be calculated using the drug's pharmacological 
parameters and dose, the MIC for the organism, the relationship between the area 
under the concentration-versus-time curve (AUC) and PAE. Xue and colleagues 
(1996) pointed out that if PAE is to be used for dosage calculation, the 
measurements of PAE must first of all be simple and reproducible, secondly 
interstrain variation should be recognised based on clinical isolates. They suggested 
that a population statistic such as the PAE for at least 90% of strains (PAE90) could 
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be used. Thirdly and finally, duration of PAE should be unaltered after multiple 
dosing (Karlowsky et al. 1993; Karlowsky et al. 1994), and must be long enough to 
have an impact on dosing interval. 
The minimum inhibitory and bactericidal concentrations (MIC and MBC) have been 
the major parameters used to quantify the activity of an antimicrobial against an 
organism. However, these parameters do not provide information about the activity 
ofhigher concentrations, the time course nor the antimicrobial effects that can persist 
after dmg exposure. Studies of antibiotic pharmacodynamics are increasingly 
looking at rate and extent of bacterial killing, effects of subinhibitory antibiotic 
concentrations, and various other factors of which PAE is one important factor. 
It has been recognised that there could be marked differences in the time course of 
antimicrobial activity among antimicrobials (Vogelman et al. 1988b; Leggett et al. 
1989; Craig et al. 1991). With certain classes of antibiotics such as aminoglycosides 
and fluoroquinolones, the rate of killing increases with increasing drug 
concentrations, a phenomenon termed concentration-dependent bactericidal activity 
(Reyman et aL 1979; MacArthur et al. 1984). Optimal use of antimicrobial agents of 
this class requires maximising peak semm levels while avoiding toxicity and several 
studies in animal models comparing different dosage regimens have demonstrated 
(Vogelman et aL 1988a; Leggett et aL 1989; Roosendaal et aL 1989) that maximal 
efficacy could be observed with dosing regimens that produce semm concentrations 
above the MIC for as little as 25% of the dosing interval. In contrast, the killing rate 
by P-lactam antibiotics is relatively slow, persists only while the concentration 
exceeds the MIC, and does not increase appreciably with increasing concentrations. 
This type of killing is termed time-dependent bactericidal activity (Eagle et aL 1950; 
Craig 1984), therefore the optimal use of p-lactam antibiotics should emphasise on 
achieving levels above the MIC continuously until the next dose. 
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The efficacy of some animal studies on once daily administration of aminoglycosides 
(Kapusnik et al. 1988; Craig et al 1991) have led to the evaluation of once-daily 
aminoglycoside dosing in humans (Mattie et al. 1989). Clinical trials comparing 
once-daily administration with two or three times-a-day dosing have, in general, 
shown equal efficacy and toxicity (Gilbert 1991; Pechere et al 1991). The clinical 
success of once-daily dosing of aminoglycosides in clinical trials suggests that PAE 
does have clinical importance (Craig and Gudmundsson 1996). 
E. PAE of Antituberculosis Drugs Against Mycobacteria 
Studies on PAE of antituberculous drugs against mycobacteria have been scarce in 
the literature. The existence of a prolonged PAE of certain antimycobacterial agents 
against M. tuberculosis has been used as support for wide dose intervals and 
intermittent drug dosing in the treatment of tuberculosis. Earlier studies showed an 
extended delay in regrowth of M. tuberculosis following a pulsed exposure of 
isolates to isoniazid and streptomycin (Dickinson and Mitchison 1966). Despite 
difficulty in separating the PAE from the bactericidal effect of these drugs, a PAE 
was thought to play a role in the delayed regrowth. It has also been shown that both 
isoniazid and rifampicin exert suppressive effects on mycobacterial growth for 
periods of up to 48 h after antibiotic concentrations in the tissues have declined to 
sub-inhibitory levels. This observation led to trials of twice-weekly drug 
administration to patients with tuberculosis and was one of the first clinical 
applications of pharmacodynamics (Beggs and Jenne 1969). 
A study on amikacin and rifapentine against a single isolate of Mycobacterium avium 
complex (MAC) has been reported and PAE was observed up to 48 h at 
concentrations of 4x and 8x MIC and exposure times of 30-120 min. A PAE of 22 h 
was seen with 10^  CFU of the M. avium during incubation for 30 min with amikacin 
at 4x MIC. These results show that amikacin, unlike rifapentine, has a long PAE 
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against M avium (Bermudez, Wu et al. 1992). Another study, again on M. avium, 
showed that despite an averaged PAE of 5.5 to 18.0 h being observed with 
clarithromycin, the addition of ethambutol did not enhance the effects (Ellis, Benson 
etal. 1995). 
F. Radiometric Measurement of Growth 
The Bactec radiometric system (Bactec TB system; Becton Dickinson Diagnostic 
Instrument, Sparks, MD) was developed based on the work of Cummings and 
Rostraph (Cummings and Rostraph 1975) and Middlebrook and associates 
(Middlebrook et al. 1977). The Bactec TB medium is an enriched Middlebrook 7H9 
broth base containing ^^ C labelled fatty acid substrate. Growth is measured by the 
Bactec instrument as the amount of ^^ CO2 released and is expressed in terms of a 
growth index (GI). The GI values are arbitrary units of radioactivity that relate to the 
actual disintegration per minute detected by the instrument (Inderlied and Nash 
1996). The GI output, however, is directly proportional to the rate and amount of 
growth in the medium. 
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IX. Materials and Methods 
A. Bacterial Strains and Their Maintenance 
Standard strain of Mycobacterium tuberculosis H37Rv (ATCC 27294) and two 
clinical isolates, TB17 & TB19, of different antimicrobial susceptibility patterns 
were studied (Table 1). The clinical isolates were identified by standard 
microbiological methods based on colonial morphology, growth rate, pigmentation 
and biochemical properties, at the Hong Kong Reference Mycobacteriology 
Laboratory in Yung Fung Shee Memorial Centre. Three sets of stock culture were 
kept, with two sets frozen at -40°C in Middlebrook 7H9 broth supplemented with 2% 
glycerol and 10% oleic acid-dextrose catalase (OADC; Difco Laboratories), and a 
third set in liquid nitrogen in horse blood. 
B. Antimicrobial Agents 
Six antimicrobial agents at their peak semm concentrations: rifampicin (16.0 mg/L), 
isoniazid (4.0 mg/L), amikacin (32.0 mg/L), ofloxacin (8.0 mg/L), levofloxacin (4.0 
mg/L) and sparfloxacin (1.0 mg/L) either alone or in combinations amongst 
themselves or with other antituberculous drugs including ethambutol (5.0 mg/L) and 
pyrazinamide (60.0 mg/L) were investigated. Rifampicin, isoniazid, amikacin, 
ethambutol and pyrazinamide were purchased from Sigma, St. Louis, USA, 
ofloxacin and levofloxacin were gifts of Daiichi, Japan, and sparfloxacin was also a 
gift ofRhone Poulenc, France. 
Stock solutions of the antimicrobial agents were prepared: rifampicin (13.8 gy^) in 
methanol, isoniazid (11.1 g/L), amikacin (61.8 g/L), ethambutol (10.9 g/L) and 
pyrazinamide (8.2 g/L) in double distilled water, and the three quinolones ofloxacin 
(29.4 g/L), levofloxacin (28.9 g/L) and sparfloxacin (5.2 g/L) in 0.1 M NaOH. 
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Aliquots of these solutions were stored at -70°C and used within six months. For 
each experiment, samples were thawed and subsequently diluted, in Middlebrook 
7H9 broth supplemented with 2% glycerol and 10% OADC for the in vitro studies or 
in RPMI 1640 culture medium enriched with 10 % human serum (blood group A, 
Rh+) for the ex vivo studies, to the appropriate concentrations. 
These antimicrobial agents and their respective concentrations based on peak semm 
levels were applied in all the in vitro and ex vivo PAE or KI studies except for the in 
vitro susceptibility testing where the drugs were prepared differently. 
C. Antimicrobial Susceptibility Testing 
The methods employed essentially followed those established by Yew and associates 
(Yew et aL 1994). 
1. Media Preparation 
Stock solutions of the six antimicrobials, rifampicin, isoniazid, amikacin, ofloxacin, 
levofIoxacin and sparfloxacin were first prepared by dissolving standard drug 
powders in a minimal volume of appropriate solvents. The working antimicrobial 
solutions were then prepared by adding the stock solutions to Middlebrook 7H9 broth 
supplemented with 2% glycerol and 10% OADC to give the highest final 
concentration desired. Two-fold serial dilutions were further made with 7H9 broth to 
give concentrations ranging from 0.03 to 8.0 mg/L. All drug media together with 
drug-free controls were incubated overnight at 37°C to check for sterility before 
inoculation. 
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The potency of each of the agents was monitored during the period of susceptibility 
study by testing their activities against standard strains of Escherichia coli NCTC 
10418 and ATCC 25922, Pseudomonas aeruginosa NCTC 10662 and Klebsiella 
pneumoniae ATCC 13883 in 7H9 broth using a micro-dilution method (Amsterdam 
1996). 
2. Bacterial Inocula 
Strains were first grown on Lowenstein-Jensen medium at 37°C for 4 to 6 weeks. A 
loopful ofcells were scraped and emulsified into 7H9 broth supplemented with 0.05 
% Tween 80 and 10% OADC and further incubated for 2 weeks. Inocula were 
prepared by adjusting the turbidity of the broth cultures with sterile double-distilled 
water to match that of McFarland 1 standard, and 0.1 mL of each culture was then 
inoculated into 10 mL each of the drug-containing medium and drug-free control. 
The inoculum size was found to contain 10^  to 10^  CFU/mL as determined by the 
viable count method. 
3. Susceptibility Determination 
After inoculation the suspensions were incubated at 37°C and growth was assessed 
weekly for four weeks. The minimal inhibitory concentrations (MICs) of the 
antimicrobials against each bacterial strain were taken as the lowest concentrations 
that resulted in complete inhibition of macroscopically visible growth after 2 weeks 
of incubation. Faint haziness or a small button of cell was disregarded. The minimal 
bactericidal concentrations (MBCs) were determined by subculturing 0.1 mL from 
bottles showing no growth on to Lowenstein-Jensen media and incubating for 4 
weeks. The MBCs were the lowest concentrations showing no visible colonial 
growth. 
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D. Assessment of PAE & KI In Vitro 
1. Vi?^ h1e rmint Method 
a) Bacteria Inocula 
Organisms were grown in Middlebrook 7H9 broth supplemented with 0.05 % Tween 
80 and 10% OADC to a density of 10? CFU/mL and were stored at -40°C in 1.0 mL 
aliquots. For each experiment, a single vial was thawed quickly at 37°C and 
inoculated into 10 mL of7H9 broth supplemented with 2% glycerol and 10% OADC 
in a screw cap bottle containing glass beads of 2-3.5 mm to aid dispersion of clumps. 
This suspension was allowed to grow for 10 to 12 days at 37°C to a density of 10^  
CFU/mL and then used as the inoculum. 
b) DeterminationofPAE&KI 
For each mn of drug-organism combination studied, 9.0 mL of drug-containing 
medium together with 9.0 mL of drug-free control were inoculated with 1.0 mL of 
the prepared bacterial inoculum. Suspensions were incubated at 37°C for 2 h. Drug 
removal was accomplished by a 10'^  dilution ( 1.0 mL in 9.0 mL and then 0.1 mL in 
9.9 mL) of the drug-exposed and unexposed control cultures into fresh prewarmed 
Middlebrook 7H9 broth containing glass beads. A drug control was included (in at 
least one mn of each of the antimicrobials studied) by inoculating similarly diluted 
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unexposed organisms into a bottle which a 10" dilution of the drug concentration had 
been made. For the study of bactericidal effects, the drug-exposed culture was 
diluted in the same manner but in the corresponding drug-containing medium. Each 
run of experiment was carried out in duplicate. 
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The viable numbers of organisms in the samples from the drug-treated and drug-free 
control bottles, immediately before and after drug exposure and at daily intervals, 
were determined by plating appropriate dilutions onto Middlebrook 7H11 agar slopes 
supplemented with 2% glycerol and 10% OADC in screw cap flasks. Growth were 
followed for a maximum of 10 days, and the agar slopes were examined after 3 to 4 
weeks of incubation at 37°C. 
PAE was calculated as the difference in time for the exposed culture and the 
corresponding control to increase by 1 logio CFU/mL immediately after dmg 
removal and by the same dilution procedures. 
The killing index (KI) was determined as the time required for a decrease of 1 logio 
CFU/mL on the bactericidal effect curve on continuous exposure of the organisms to 
the respective antimicrobial agents. 
2. Radiometric Method 
a) Bacteria Inocula 
Initially, strains to be tested were grown on Lowenstein-Jensen medium at 37°C for 3 
weeks. Cells were scraped and emulsified into Bactec special diluting fluid in a 
screw-cap bottle containing glass beads. A homogenous suspension of cells was 
obtained by mixing with a vortex for 5 minutes and then leaving it in an upright 
position for at least 30 minutes or until the large particles had settled. The 
supernatant was carefully transferred into another sterile bottle and the turbidity 
adjusted to match that of McFarland 1 standard by adding more special diluting 
fluid. Aliquots of 1.0 mL were dispensed and stored at -40°C. Prior to use, a vial 
was thawed quickly at 37�C and inoculated into 10.0 mL of Bactec 12B medium 
supplemented with 2.5% PANTA reconstituting fluid (PRF). This suspension was 
incubated for 10 to 12 days at 37°C and used as the inoculum. 
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b) Determination of PAE 
The procedures adopted was the same as those in the viable count method except that 
the 10_3 dilution (1.0 mL in 9.0 mL and then 0.1 mL in 9.9 mL or 0.4 mL in 9.6 mL 
and then 0.1 mL in 4.0 mL) for dmg removal was achieved with Bactec 12B medium 
supplemented with 2.5% PRF in Bactec vials instead. 
All Bactec vials were read by a BACTEC 460 instrument (Becton Dickinson 
Instrument Systems, Towson, Maryland) prior to inoculation to eliminate any vials of 
high background readings and to enrich the vials with a 5% CO2 atmosphere. The 
inoculated Bactec vials were incubated at 37°C and were read daily within 2 hours of 
the time the vials were inoculated on the first day in the BACTEC 460 reader until 
the Bactec Growth Index (GI) of all vials reached 999. 
For analysing growth inhibition or delay with respect to the growth index, a method 
devised, for measuring the MIC of M. avium, by Inderlied and associates (Inderlied, 
Young et al. 1987) was employed. A value termed TlOO was defined as the time 
necessary for a culture to produce a cumulative GI value of 100. The TlOO value is a 
measure of both the lag and steady-state time of ^^ CO2 production. The cumulative 
GI versus time was then related to the growth pattern generated by the viable count 
method for the determination of the delay of growth after drug-treatment to reveal the 
PAE. 
E. Assessment ofPAE & KI Ex Vivo 
1. Human Leukaemic Monocytic Cell Line 
A human leukaemic monocytic cell line, THP-1 (Tsuchiya et aL 1980) was used for 
the study of PAE ex vivo as well as drug uptake. The cell line was a generous gift 
from Professor R. Wise, Birmingham City Hospital, Birmingham, UK. 
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a) Growth media and maintenance 
The medium for the growth of THP-1 cell line was RPMI 1640 (Gibco BRL) 
supplemented with 5 % NaHCO3 (7.5%, w/v), 2.4 % HEPES buffer , 0.8 % filter-
sterilised glutamine solution ( 150 mM ), 0.48 % gentamicin (4 mg/mL) and 10 % 
heat inactivated (56�C for 30 minutes) fetal bovine serum. 
THP-1 cells, grown to a cell number of approximately 8 x 10^  cells/mL as determined 
by visual count using a Neubauer cell count chamber under a light microscope, were 
kept in RPMI 1640 with 20 % dimethylsulfoxide (DMSO) and 50 % human semm 
(blood group A, Rh+) and stored in liquid nitrogen. 
b) Culture conditions 
The THP-1 cells taken from liquid nitrogen storage were thawed quickly at 37°C. 
The DMSO in medium was removed from the cells quickly by washing twice with 
tissue culture medium RPMI supplemented with 10 % fetal bovine semm through 
centrifugation at 501 x g (Megafuge 1.0, Heraeus SEPARECH, Germany) for 5 
minutes at room temperature. The cell pellet was resuspended in RPMI culture 
medium enriched with 10 % fetal bovine serum. The number of cells was estimated, 
and diluted to approximately 5 x 10^  cells/mL for subsequent culture in the 
aforementioned medium and was incubated at 37�C in a 5 % CO2 incubator for 4 to 5 
days. When the cell number reached 8-10 x 10^  cells/mL, the cell culture was 
separated into aliquots at a suitable concentration of 3 x 10^  cells/mL for further 
growth. 
c) Uptake of M. tuberculosis 
When the number of THP-1 cells reached 9-10 x 10^  cells/mL, the culture medium 
was changed through centrifugation at 501 x g for 5 minutes and the cell pellet was 
-3 . . 
resuspended in same volume of fresh medium. Retinoic acid (10 M, dissolved in 
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ethanol) was added to a final concentration of 10'^  M to trigger THP-1 monocytic 
cells to differentiate into macrophages. After 3 days of incubation at 37�C in 5% 
CO2, the differentiated cells were pelleted (501 g for 5 minutes) and resuspended in 
same volume of fresh and prewarmed culture medium enriched with 10 % human 
serum. Logarithmic-phase mycobacterial cells were added to the differentiated THP-
1 cells at a 1:1 multiplicity of infection. Bacterial aggregates were dispersed prior to 
infection by sonication for 3 minutes in a Branson Ultrasonic waterbath (Bransonic 
3210) at 37�C. The cell mixtures were centrifuged at 174 g for 10 minutes at room 
temperature and then incubated at 37�C in 5% CO^ for 2 hours. After incubation, 
the infected cells were ready for studies of drug uptake or PAE and KI ex vivo. 
2. Determination ofPAE & KT Ex Vivo by the Radiometric Method 
Mycobacterium tuberculosis, previously prepared in the same manner as in vitro, 
phagocytised by macrophages differentiated from THP-1 cells were exposed for 2 
hours to various antimicrobials alone or in different combinations at the 
concentrations outlined above. One millilitre samples of drug-treated and untreated 
control cells containing the bacteria were then washed twice with 0.93 mL sterile 
phosphate-buffered saline, through centrifugation at 2000 g (MSE Micro-Centaur 
Centriftige, Sanyo Gallenkamp) for 4 minutes and aspirating 0.93 mL of the 
supernatant, for removal of antimicrobials and extracellular bacteria. The final 
suspension (0.1 mL) was then inoculated into a Bactec vial for the determination of 
growth in terms of Growth Index, and PAE ex vivo was determined using the same 
principle as reported for the PAE in vitro using the Bactec system, again TlOO was 
measured for the determination ofPAE. 
The viable numbers of intracellular organisms immediately before and from 
continuous exposure to various drugs were determined for the study of bactericidal 
effects (KIs) ex vivo. One millilitre samples of cells taken accordingly were 
submitted to a first washing of sterile phosphate-buffered saline and subsequently 
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lysed by a second washing of Middlebrook 7H9 broth containing 2% saponin (v/v). 
Aliquots of the lysates were plated after appropriate dilutions onto Middlebrook 
7H11 agar medium and the number of CFU counted after 3 to 4 weeks of incubation 
at 37�C. 
F. Determination ofDmg Uptake 
For each ofthe drugs studied, three 1.0 mL samples were taken before exposure and 
at intervals of 15, 30, 60, 90, 180 & 240 minutes after exposure. Immediately after 
each taking, THP-1 cells were separated from the extracellular antibiotic by 
centrifugation at 3000 g (MSE Micro-Centaur Centrifuge) for 15 minutes. The 
supernatant and the cell pellet were then stored separately at -70°C until used. 
Uptake analysis of THP-1 cells of rifampicin, isoniazid, and the three quinolones 
were performed with high-performance liquid chromatography (HPLC) while 
amikacin was analysed by the fluorescence polarization immunoassay using the 
TDxFLx system (Abbott Laboratories, USA) 
1. High-Performance Liquid Chromatography 
HPLC assay procedures were performed according to those developed by Chan 
(Chan 1988; Walubo et aL 1991) and those described by Chan and associates (Chan 
et aL 1989;Lyon et aL 1994) 
All chemical reagents used were of analytical or HPLC grade and were purchased 
from E. Merk, Darmstadt, Germany. Double distilled water was used throughout the 
studies. All mixtures for mobile phases were filtered and degassed prior to use. 
Solutions of known concentration were included, at the beginning and the end of 
each batch of samples, as external standard quantitatively. 
25 
a) Equipment 
The HPLC apparatus consisted of a 2150 HPLC pump, 2151 variable wavelength 
monitor, 2210 dual channel recorder (LKB products, Sweden) and a 7125 sample 
injector (Rheodyne Inc., USA). The stationary phase was a Radial-Pak™ cartridge 
(8 mm X 100 mm, 4 i^m; Waters) which is equivalent to a C18 reversed phase 
column. The chromatograms were recorded at a chart speed of 2 mmAnin. 
b) Chromatographic Conditions 
(i) Rifampicin 
The mobile phase, a mixture of 45 % acetonitrile in 10 mM potassium dihydrogen 
phosphate at pH 3.5, was delivered at a flow rate of 1.5 mL/min. Monitor 
wavelength was set at 215 nm. 
(ii) Isoniazid 
The mobile phase was a mixture of acetonitrile: water: triethylamine (70: 30: 0.4 v/v) 
containing 5 mM heptanesulphonic acid adjusted to pH 6.0, was delivered at a flow 
rate of 1.0 mL/min. Monitor wavelength was set at 320 nm. 
(iii) Quinolones 
The mobile phase, consisting of methanol : acetonitrile : 0.4 M citric acid (3:1:10 
v/v), was delivered at a flow rate of l .0 mL/min. Monitor wavelength was set at 275 
nm. 
c) Sample Preparation 
(i) Rifampicin 
To each 0.5 mL of sample in a glass tube, 0.5 mL of methanol, for precipitation of 
protein, and 1.0 mL of 1.0 M phosphate buffer containing 2% ascorbic acid was 
added with pH adjusted to 4.2. Seven millilitres of a mixed organic solvent 
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consisting of dichloromethane-diethylether (2 : 3 v/v), for extraction of the drug, 
were then added to the mixture. The resulting emulsion was thoroughly mixed for 15 
minutes with an automatic shaker and then centrifuged at 3000 g for 10 minutes to 
separate the organic layer. The top organic phase was transferred to another tapered 
base glass tube and dried under a stream of nitrogen. The extraction procedure was 
repeated once before the final residue was dissolved in 0.075 mL of methanol, and 
0.01 mL ofthe solution was injected into the HPLC system for analysis. 
(ii) Isoniazid 
To each 0.5 mL sample, adjusted to pH 4.0 with 0.1 mL acetic acid, 5.0 mL of n-
hexane was first added and shaken. Impurities were removed from the mixture 
through centrifugation at 3000 g for 10 minutes and the top organic layer discarded. 
The sample was derivatized by adding 0.3 mL of an ethanol solution containing 
salicylaldehyde (0.1% v/v) and 0.4 mL of 10% aqueous acetic acid, and heated in a 
water bath at 60°C for 30 minutes. After cooling to room temperature, 1.0 mL of l .0 
M dipotassium hydrogen phosphate buffer (pH 6.5) was then added to the mixture 
and shaken for 10 second to remove any excess salicylaldehyde. Five millilitres of 
diethyl ether were further added to the derivatized mixture, which was then shaken 
(10 minutes) and centrifuged (3000 g for 10 minutes). The extracted salicyhydrazone 
and azine contained in the top organic layer was subsequently transferred and dried 
under a stream of nitrogen. The residue was finally dissolved in 0.1 mL of the 
appropriate mobile phase solution and 0.02 mL of the resulting solution was injected 
into the HPLC system for analysis. 
(iii) Quinolones 
To each 0.1 mL of sample, an equal volume of 1.0 M perchloric acid was added, 
shaken and incubated at 55°C for 15 minutes. The precipitated mixture was then 
centrifuged at 10,000 g for 5 minutes, and 0.01 mL of the clear supernatant was then 
injected into the HPLC system for analysis. 
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2. TDxFLx Assay for Amikacin 
Analysis of samples for amikacin was achieved using the instrument TDxFlx (Abbot, 
Chicago, USA) which is an automated fluorescent polarization analyser. The 
analytical procedures were followed according to the manufacturer's instruction 
including the construction of a calibration curve and parallel running of standards of 
high, medium and low concentrations for internal control. 
3. Estimation ofDmg Concentrations 
The mean cell volume ofTHP-1 cells was determined using the Autocrit II centrifuge 
(For determination of whole blood micro-hematocrits, Clay Adams, Becton 
Dickinson & Co., USA). Extracellular concentrations of the various antituberculous 
drugs were expressed as mg of drug assayed per mL of the cell culture supernatant 
while the intracellular concentrations of drugs were expressed as mg of drug assayed 
per mL ofthe macrophages differentiated from the THP-1 cells. The volume of cells 
were calculated as the number of cells determined by microscopic counts times the 
mean cell volume of the macrophage. 
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X. Results 
A. In Vitro Susceptibility Testing of the M. tuberculosis Strains 
Initial screening of the susceptibility pattern of the three selected M. tuberculosis 
isolates against the commonly used first-line drugs of rifampicin and isoniazid 
revealed that the standard strain H37Rv and clinical isolate TB19 were sensitive to 
both drugs while the clinical isolate TB17 was resistant (Table 1). When the three 
isolates were tested in vitro against amikacin and the three quinolones, ofloxacin, 
levofloxacin and sparfloxacin, it was found that all the quinolones gave low MICs 
and MBCs ranging from 0.03 mg/L to 1.0 mg/L and 0.06 mg/L to 1.0 mg/L 
respectively, irrespective of their sensitivities to rifampicin and isoniazid (Table 1). 
Sparfloxacin showed the lowest MIC (0.03 mg/L) and MBC (0.06 mg/L) while 
amikacin showed MICs of 1.0 mg/L with MBC varied from 1.0 mg/L to 4.0 mg/L 
depending on the isolates (Table 1). 
B. PAE In Vitro - the Classical Viable Count Method 
The PAE in vitro of standard strain H37Rv after 2 hour of exposure to rifampicin as 
determined by the standard viability counts was deduced from drug-treated and 
untreated growth curves - a colony count versus time plot (Figure 1). The PAEs in 
vitro of other drugs tested against the selected isolates (Table 2) were deduced based 
on growth curves similar to Figure 1. Rifampicin, when used against H37Rv, gave 
the longest PAE in vitro (45.6 h) with a residual effect of 3.0 h (Table 2). Isoniazid, 
amikacin and the quinolones all produced relatively short PAEs in vitro (0.9 h to 
27.4 h) compared to that of rifampicin, with varying residual effects ranging from 2.9 
h for isoniazid, 6.1 h for amikacin and negligible time for the quinolones (Table 2). 
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C. PAE Measured by the Bactec Method 
The growth of mycobacteria as measured by ^^02 liberated was detected by the 
Bactec 460 instrument and expressed as growth index (GI) values ranging from 0 to 
999. Cumulative growth indices in semilog plotted as a function of time behaved 
similarly as a sigmoid standard growth curve but differed in the initial lag time 
(Figure 2a). On the basis of cumulative growth indices, the time required to achieve 
cumulative values of 10, 100, & 1000 (termed T10, TlOO & T1000) at various 
inoculum size were plotted (Figure 2b), which allowed TlOO to be chosen for 
determination of PAE in vitro by the Bactec method as the slopes generated at 
different cumulative values showed slight variations. 
When PAEs in vitro of the six antituberculous drugs against M tuberculosis H37Rv 
obtained by the Bactec method based on TlOO readings were compared to those 
obtained by the viable count method (Figure 3, Table 3), it was found that readings 
obtained by the Bactec method gave a longer PAE for drugs other than the 
quinolones, with rifampicin giving the longest PAE of 58.1 h, followed by amikacin 
(19.2 h) and isoniazid (11.5 h). However, there were no detectable PAEs for 
quinolones using the Bactec method (Table 3). 
D. PAE In Vitro _ the Bactec Method 
Further studies on postantibiotic effects in vitro using the Bactec method were 
performed for the three selected M. tuberculosis isolates against the six 
antimicrobials. First-line antituberculosis drugs and amikacin induced PAEs and 
residual effects of various length ranging from 0 h to 84.6 h and 0 h to 59.4 h, 
respectively (Table 4). Rifampicin gave the longest PAEs and residual effects against 
the two sensitive isolates (Figure 4, Table 4), while against the resistant strain TB17, 
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no PAE nor residual effect was found (Table 4). Amikacin gave moderate PAEs of 
16.9 h to 43.6 h with residual effects of 0 h to 12.9 h (Figure 3, Table 4) irrespective 
of the drug susceptibility pattern of the isolates. None of the quinolones studied 
produced any PAE against all of the three isolates, however small residual effects 
were found with ofloxacin and sparfloxacin against TB19. 
E. Postantibiotic Effects Ex Vivo by the Bactec Method 
1. Antitubercu1ous Drugs Uptake by THP-1 Differentiated Macrophage 
When the THP-1 differentiated macrophages after infection by M tuberculosis 
H37Rv were exposed to peak serum levels of the various antituberculous drugs, it 
was found that all of the drugs penetrated into the macrophages with varying 
concentrations (Figure 5, a-f), and the uptake kinetics followed similar patterns. 
Extracellular concentrations remained more or less constant while intracellular 
concentrations generally followed an initial uptake phase followed by a slight decline 
to a plateau between 90 to 240 minutes after drug exposure. At two hours after 
exposure to rifampicin, isoniazid, amikacin, ofloxacin, levofIoxacin and sparfloxacin, 
the intracellular concentration increased ranging from over 100 fold for isoniazid, 35 
fold for rifampicin, 5 fold for amikacin, and 6 to 10 fold for the quinolones (Table 5). 
2. PAEs Ex Vivo 
When the intracellular and extracellular growths of M. tuberculosis isolates were 
compared using the Bactec system with drug-free medium, it was found that the 
organisms grown both intracellularly and extracellularly produced similar TlOO 
values of 100 h and 95 h respectively. 
PAEs determined ex vivo for H37Rv phagocytised by THP-1 cells against 8 
antimicrobial agents alone and in combinations (represented by Figure 6) showed 
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that when the drugs were used alone, rifampicin gave the longest PAE of 72.7 h 
while the others gave PAEs varying from 0.2 h to 11.6 h (Table 6), with sparfloxacin, 
levofloxacin and ethambutol giving negligible PAEs. PAE ex vivo was also 
determined for a combination of drugs using the TlOO value from the cumulative 
growth index curve (Figure 6) and it was found that the combination of HRZ had a 
PAE of 96.7 h. Among all the combinations employed, PAEs of a wide range were 
recorded (Table 6) based on analyses similar to those in Figure 6, and HRZM was 
found to induce the longest PAE of 119.1 h while ORM gave the shortest PAE of 
17.9 h, and similar PAEs of97.2 h, 96.7 h and 95.0 h were obtained by combinations 
ofHRA, HRZ and ORA respectively (Table 6). 
F. Bactericidal Activities In Vitro and Ex Vivo 
The killing indices (KIs) in vitro of the six drugs against the three isolates of M. 
tuberculosis were determined by plotting ofbactericidal effect curves (Figure 7). The 
best rates of killing in vitro were observed from M. tuberculosis H37Rv exposed to 
rifampicin and isoniazid (8.2 h and 9.2 h respectively), but when tested on the 
resistant isolate TB17 there was little effect or no killings observed (Table 7). 
Amikacin killed the three isolates at similar rates of 32.7 h, 33.9 h and 50.0 h 
irrespective of their subsceptibilities to the first-line antituberculous drugs since they 
were sensitive to amikacin (Table 1). The three quinolonies gave in vitro 
bactericidal indices (KI) ranging from 41.9 h to 92.2 h (Table 7) with levofloxacin 
giving the strongest bactericidal effect. 
The killing indices ex vivo on M. tuberculosis H37Rv in THP-1 differentiated 
macrophages generated from single drug exposure showed that ofloxacin was the 
most bactericidal with a KI of 3.0 h, followed by rifampicin (5.8 h); and the rest of 
the drugs were less bactericidal with KI ranging from 13.1 h for ethambutol to the 
longest KI of 49.4 h for sparfloxacin (Table 8). When the same isolate were tested 
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against a combination of drugs for bactericidal effects, it was found that all the 
killing indices were reduced in general, ranging from 0.4 h for HRA to 5.2 h for 
ORZA (Table 8). It should be noted that the killing index for HRZ was so low that 
generation ofthe reading by viable count was beyond measurement (Table 8). 
33 
XL Discussion 
A. Selection of M. tuberculosis Isolates and Drug Susceptibility 
Three isolates of M. tuberculosis were studied, including a standard strain ofH37Rv, 
and two clinical isolates ofTB17 and TB19. The standard strain H37Rv was chosen 
because it is a reference in almost all kinds of studies for tuberculosis, and it is an 
isolate that is susceptible to most known antituberculous drugs. Clinical isolates of 
TB17 & TB19 were chosen according to their drug susceptibilities, TB19 like the 
standard strain is sensitive to all antituberculous drugs tested while TB17 is an isolate 
which is multiple-resistant to the first-line drugs but sensitive to amikacin and the 
quinolones studied (Table 1). All the 3 quinolones tested were active against all the 3 
M.tuberculosis strains tested, including the MDR strain TB17, which was resistant to 
first-line antituberculosis drugs, and rendered them to behave as susceptible as the 
drug-susceptible isolates. Sparfloxacin MICs (range, 0.03 to 0.125) were 1 to 2 
dilutions lower than those of ofloxacin and levofloxacin. In spite of differences in 
the MICs among the three quinolones, the MICs of individual quinolone were within 
a small range for all 3 strains, suggesting that the activities of quinolones remain 
unaltered in the case of MDR-TB isolates resistant to routinely used first-line drugs 
which agreed to findings in the literature (Rastogi, Goh et aL 1996). The same 
observation was also found in amikacin which is a second- or third-line 
antituberculosis drug (Table 1). 
B. PAE and KI In Vitro & Ex Vivo - the study methods 
Most of the in vitro studies of PAE have made use of the classical viable count 
method to measure the growth kinetics of the drug-exposed organisms and 
unexposed control and made use of the formula 'PAE = T - C' (McDonald et aL 
1977; Bundtzen et aL 1981; Craig and Gudmundsson 1986 ) where 'T' is the time 
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required for the bacterial counts of the exposed cultures to increase 1 logio above the 
counts observed immediately after dmg removal and 'C' is the corresponding time 
required for the counts of the untreated cultures. Control growth curves at different 
inocula and determination of the number of bacteria after dmg removal were done to 
ensure that drug-exposed and control cultures were compared at similar inocula. Ex 
vivo or in vivo studies of PAE and KI would follow the same study design using 
viable colony counts with the drug-exposed and unexposed organisms obtained from 
a cell-line or animal after infection. Our preliminary study ofPAE and KI in vitro of 
the six antituberculous drugs against isolates of M tuberculosis also made use ofthe 
viable count method which has generated reasonable results (Table 2, 3, 7; Figure 1, 
7). However, it was soon realised that the methods had several disadvantages which 
included the large erratic range of data probably due to clumping of organisms, time-
and labour-consuming procedures, and high risk for the laboratory researchers since 
samples needed to be plated repeatedly. The study methodology ofPAE in vitro was 
then changed to the use of the radiometric liquid culture medium of the Bactec 460 
system. 
All the preliminary works for PAE studies in vitro using the Bactec system did not 
differ from those of the viable count method. However, growth measurement by the 
Bactec system which is by instrumentation detection of the liberation of radioactive 
carbon dioxide did not only indicate the bacterial growth in increase in numbers but 
also growth with respect to metabolism. Owing to the increase in sensitivity of 
growth measurement and by instrumentation other than manpower, results could be 
obtained in days instead of weeks and the laboratory procedures became less tedious 
with workers exposed to less biohazards. PAE measured using the Bactec system 
would be more consistent without the flawed assumption of one to one relationship 
between a CFU and a bacterium of the viable counts, therefore avoiding the problem 
ofunderestimating PAE due to filamentation or overestimating PAE due to clumping 
of post-treatment bacteria. 
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Since there was a change in the measurement of growth of the M. tuberculosis 
isolates before and after drug exposure, an analytical scheme based on a 
susceptibility study of drugs against M avium (Inderlied et aL 1987) was modified 
and introduced for analysing growth inhibition or delay with respect to the growth 
index (Figure 3). A value termed TlOO was introduced and defined as the time 
necessary for a culture to produce a cumulative GI value of 100 which was used as a 
standard checkpoint for the measurement of growth delay expressed by the 
cumulative growth index versus time, and such delay could be referred to as PAE 
after verification with preliminary results obtained from the viable count method 
(Table 3). 
The radiometric method utilising the Bactec system was also applied for our further 
study of PAE ex vivo, and it has been repeatedly proven to be more convenient and 
easy-to-handle which allowed more sets of experiments to be performed within a 
shorter period of time. Since the use of the radiometric method in the elucidation of 
PAE would not only measure the delay of growth in cell numbers but also the delay 
of metabolism, this method would be more favourable if one has to consider the 
more in-depth definitions of PAE and the related phenomena rather than looking at 
growth suppression alone (Shibl et aL 1995). However, since the system only 
measures the liberation of carbon dioxide as a result of growth and metabolism, 
killing indices (KI) in vitro and ex vivo could not be obtained and the classical viable 
count method had to be followed. 
C. PAE In Vitro & Ex Vivo - single drug 
Our results on PAE in vitro and ex vivo of the six antituberculous drugs used alone 
using the viable count (Table 2, 3) or the radiometric methods (Table 3, 4 & 6) have 
indicated that the longest PAE with slight residual effects were obtained by 
rifampicin, followed by isoniazid, which concurred with the findings in older 
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literature where growth delay was reported when M. tuberculosis isolates were 
exposed to pulse or intermittent therapy with isoniazid and rifampicin (Dickinson 
and Mitchison 1966). It should be noted that the antituberculous drugs would 
produce no PAE in vitro if they were used against an isolate which was resistant to 
the particular drugs as in the case ofTB17 to rifampicin and isoniazid (Table 4), but 
the PAE in vitro of the drugs to which the organism is susceptible remained 
unchanged (Table 4). Our findings on PAE in vitro and ex vivo of amikacin and the 
negligible PAE and residual drug effect produced by the three quinolones of 
ofloxacin, levofloxacin and sparfloxacin (Table 2,3,4 & 6) have never been reported 
in literature and it would be important to note that the variation of PAE remained 
small for the individual drug against different isolates of variable drug susceptibility 
profiles as long as the organism is sensitive to the particular drug (Table 2,4). It 
should also be noted that we have considered PAE of less than 24 h to be 
insignificant for antituberculous drugs since most of the chemotherapeutic regimens 
for tuberculosis would be given daily, in alternate days, or even thrice weekly; a PAE 
of less than 24 h would therefore have no impact on the present regimens. 
When PAEs of the six antituberculous drugs used alone obtained from the ex vivo 
model ofTHP-1 cell differentiated macrophages (Table 6) were compared to those 
obtained from the in vitro studies (Table 4), similar or extended PAEs were observed, 
with the exception of amikacin which has a shorter PAE ex vivo. Ofloxacin which 
gave negligible PAE in vitro (Table 2-4) had a slightly extended PAE ex vivo (Table 
6). Drug uptake studies have demonstrated that all of the antituberculous drugs used 
penetrated and were concentrated in the macrophages (Figure 5, a-f), with an increase 
in intracellular concentrations from 6-8 fold for quinolones to 35 and 100 fold for 
isoniazid and rifampicin, respectively (Table 5). This might account for the increase 
in PAE ex vivo since the macrophages alone would have no intracellular killing effect 
against these facultative intracellular parasites of M. tuberculosis as further proven 
by our control study comparing growth rates of the organisms in drug-free medium 
and drug-free macrophages. Although it has been reported that rifampicin possessed 
impressive activity in human macrophages (Crowle et aL 1988), and that both 
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rifampicin and isoniazid were shown to be accumulated rapidly within phagocytes 
(Johnson et aL 1980; Prokesch and Hand 1982) and became highly active in THP-1 
macrophages against intracellular M. tuberculosis (Arain et aL 1996) even at the 
same concentration as the MIC determined in vitro (Clini and Grassi 1970), it would 
seem that the increase in intracellular dmg concentrations may not be used as the sole 
explanation for the extended PAE ex vivo since it cannot explain the reduction of 
PAE ex vivo of amikacin, not to mention the conflicting report showing that none of 
the rifamycins were concentrated in macrophages (Dhillon and Mitchison 1992), 
while the MICs were higher in the macrophages than in vitro by a factor 6.7-fold for 
rifampicin with unknown mechanism. It is difficult to explain the phenomenon 
observed for amikacin, however, two possible explanations might be offered, the first 
being the unsuitable assay procedure used for amikacin as the TDxFLx 
instrumentation is designed for the use of semm samples instead of tissue culture 
media which might give erratic readings, and the second on the potency of the dmg 
which could not be elucidated by an immunoassay. 
D. PAE Ex Vivo - drug combinations 
Studies on PAEs in vitro or ex vivo of antituberculous drugs used in combinations 
have never been reported in the literature, and our present study has only made use 
of the ex vivo system since we would consider it to be closer to the in vivo or in situ 
conditions. The combinations of drugs tested in this study were recommended by 
Dr. W. W. Yew (personal communication) since some of these combinations have 
been used with success in treating patients with tuberculosis especially those 
regimens including the use of ofloxacin (Yew et aL 1990; Yew et aL 1992). 
Rifampicin was included in all the regimens tested because it has remained as the key 
antituberculous drug in first-line therapy. Results from our study (Table 6) indicated 
that PAEs ex vivo of combined drugs may be longer or shorter than the longest PAE 
observed when the drugs were used alone. Combinations such as HRZ, HRA, ORA 
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and HRZM provided extended PAEs of 95 to over 110 h while HRM, ORM, HRZA, 
ORZA and ORZM gave reduced PAEs compared to the PAE observed with 
rifampicin alone. It was observed that the substitution of isoniazid with ofloxacin in 
the combined regimens would generally reduce the PAE (Table 6). It was also noted 
that pyrazinamide and amikacin may be antagonistic to each other since both 
combinaitons HRZ and HRA gave PAEs as much as 50 h longer than the PAE 
measured with the combination HRZA. On the other hand, pyrazinamide and 
ethambutol may be synergistic with each other as the combination HRZM gave PAEs 
20 and 70 h longer than the combinations HRZ and HRM, respectively (Table 6). It 
is not surprising to see extension or reduction ofPAE by combined drugs since there 
have been reports on synergism, indifference as well as antagonism when several 
antituberculous drugs were used in combination against M. tuberculosis (Dickinson 
et aL 1977). Other quinolones were not tested in our study because they have not 
been considered as established antituberculous drugs. No explanation other than 
additive effects can be offered at this stage for the extension of PAE found in 
combined regimens, and perhaps an example on the additive or synergistic activity 
ofethambutol combined with other agents being postulated to be due to alteration of 
the mycobacterial cell wall by ethambutol allowing enhanced uptake of other drugs 
(Deng et al. 1995) might also add to the explanation, however, more detailed studies 
on dmg interactions, pharmacokinetics and pharmacodynamics would be needed to 
elucidate the mechanism. 
E. KI In Vitro & Ex Vivo 
Our studies on the bactericidal effects of the antituberculous drugs used alone or in 
combinations expressed as KI in vitro and ex vivo indicated that all the drugs could 
provide bactericidal activities at their peak serum levels (Table 7) or at concentrated 
intracellular levels (Table 8). When the antituberculous drugs were used alone, 
rifampicin would provide the best killing index in vitro, followed by isoniazid and 
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the quinolones (Table 7). It should be noted that the antituberculous drugs would 
have a prolonged KI if they were used against an isolate which is resistant to the 
particular drugs, but the KI of the drugs to which the organism is susceptible would 
remain unchanged (Table 7). 
Examination ofKI ex vivo (Table 8) of the antituberculous drugs used alone revealed 
that there were improvements for rifampicin, levofIoxacin and ofloxacin, especially 
the latter two drugs giving a respective 10 h and 10 fold decrease of KI when 
compared to its KI in vitro (Table 7), which was probably due to the increased 
intracellular drug concentrations (Table 5). However, these improvements were not 
observed in amikacin or sparfloxacin (Table 8) even though the intracellular drug 
concentrations were found to increase as demonstrated by the HPLC assays or the 
fluorescent polarization immunoassay and perhaps similar explanations 
abovementioned for the PAE ex vivo of amikacin might be applied. 
When KI ex vivo (Table 8) of the antituberculous drugs used in combinations were 
examined, it was noted that there were overall significant improvements of 
bactericidal activities for drug combination, with some of the KI being greatly 
reduced even beyond measurable time (0 h for HRZ, 0.4 h for HRA & 0.6 h for 
HRM, Table 8) since the viable count measurement were only taken daily and the 
killing might have been be too fast to be out of catch by such method. Improvements 
in KI may be explained by the presence of synergistic effects on which most of the 
clinical chemotherapeutic regimens have been based. By a broad definition synergy 
is referred to the net antimicrobial activity resulting from two or more drugs that is 
greater than the sum of their independent contributions. Demonstration of synergy or 
antagonism between antibiotics by time-kill study generally correlate with outcome 
of therapy (Kobasa et aL 1983; Chandrasekar, et aL 1987; Kim 1987; Hilf et aL 
1989). The resultant rate of bactericidal activity can be used to define synergy as a 
decrease of 2 log units in CFU for the combination of the two agents, compared to 
the activity of the most active single agent. In our findings ofKI ex vivo between the 
individual drugs and the combinations (Table 6), it would be reasonable to deduce 
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that the improvement of KI was mainly due to dmg synergy based on the above 
definition. 
F. PAE and Clinical Therapeutic Regimens 
Mycobacterium tuberculosis is naturally resistant to most antimicrobial agents 
probably as a result of its highly lipophilic cell envelope acting as an effective 
barrier. Problems of resistance leading to therapeutic failure were often encountered 
when antimicrobials were employed singly (Youmans et aL 1946; Pyle 1947), this 
led to the use of multidrug therapy. The main drugs currently used for the treatment 
of tuberculosis are isoniazid, rifampicin, pyrazinamide, streptomycin and 
ethambutol. Both isoniazid and rifampicin are very potent bactericidal drugs as well 
as very effective in preventing the emergence of dmg resistance. Rifampicin can kill 
intermittently metabolising bacilli after a short exposure to the drug, while isoniazid 
kill some 90% of actively growing tubercle bacilli during the first few days of 
chemotherapy but its action takes place after the organisms have been exposed to the 
drug for 24 h. Pyrazinamide is a very important sterilising dmg as it can kill 
intracellular bacilli that are protected inside macrophages. Streptomycin and 
ethambutol are less bactericidal and less effective in preventing emergence of drug 
resistance. They are added when pre-treatment resistance is suspected. 
The increasing incidences of M. tuberculosis resistant to two or more antituberculosis 
drugs have heightened interest in the development of new agents. Agents of the 
fluoroquinolone class which have shown distinct activity against M. tuberculosis 
(Rastogi and Goh 1991; Yew et aL 1994) seemed the most promising since they are 
being orally administered, well tolerated with minimal side effects (Kennedy et aL 
1993; Beming et aL 1995) and not cross resistant to other class of antituberculosis 
drugs (Rastogi et aL 1996). In cases of tuberculosis where patients suffered from 
hepatic dysfunction, usually isoniazid or occasionally rifampicin would be replaced 
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by other drugs since liver damage has been observed more frequently in patients 
given rifampicin plus isoniazid compared with rifampicin plus other anti-TB drugs. 
Fluoroquinolones, particularly ofloxacin, is recommended as a component dmg, and 
favourable results have been obtained in the treatment of multiple drug resistant 
pulmonary tuberculosis (Yew et aL 1990; Willcox 1993; Schaberg et aL 1995) and in 
tuberculosis patients with hepatic dysfunctions (Yew et aL 1992; Yew et aL 1995). 
For rational planning of a regimen, in addition to the pharmacokinetics and 
pharmacodynamic data, the potential impact of parameters such as bactericidal 
killing in terms of EBA, and the presence or absence of PAE should be considered. 
The minimum inhibitory and bactericidal concentrations (MIC and MBC) are the 
primary pharmacodynamics used to characterise a drug's antibacterial activity in 
vitro. However, these values provide very limited information on the time course of 
a drug's activity. For example, the MBC does not provide information on the rate of 
killing of a dmg nor whether it can be enhanced by increasing dmg concentrations. 
Likewise, the MIC does not reflect whether a dmg can inhibit bacterial growth 
beyond the time of exposure. It is likely that the kinetics of bacterial killing and the 
PAE would be better in describing the time course of antibacterial activity for 
different drug-organism combinations. 
Information on the interaction between an antimicrobial agent and organism obtained 
from a PAE test, which traditional susceptibility tests and pharmacokinetic study do 
not provide, has been regarded as an important pharmacodynamic parameter in 
determining an optimal dosing regimen for the antimicrobial agent (Vogelman et aL 
1988). There are numerous effective regimens with different drug combinations for 
treating pulmonary tuberculosis. The shortest duration of treatment is 6 months for 
uncomplicated susceptible culture or smear-positive pulmonary tuberculosis is 2 
months ofHRZ followed by 4 months ofHR taken daily, twice weekly or three times 
weekly (Wolinsky 1993; American Thoracic Society 1994). Streptomycin or 
ethambutol is included in the initial phase when there is a concern of initial dmg 
resistance to isoniazid or isoniazid and streptomycin. However, these regimens are 
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not effective when there is rifampicin resistance. For clinically diagnosed pulmonary 
TB, but without bacteriological findings, four-month regimens of HRZ for 2 months 
followed by HR for another 2 months taken daily or thrice weekly are recommended. 
For cases of tuberculosis resistant to isoniazid and rifampicin or more, there are no 
specific guidelines. In general a regimen should be tailored based on sensitivity tests 
with the concentrations of antimicrobials tested chosen at the peak concentrations 
attainable with the current dosages for the human disease. Current CDC 
recommendations are at least four drugs initially including at least three drugs, and as 
many first-line drugs, to which the organisms are susceptible (Centers for Disease 
Control 1993a). All the abovementioned regimens included the use of rifampicin 
and mostly isoniazid which were given in alternate days or thrice weekly. Our study 
on PAE in vitro & ex vivo for these drugs used alone or in combination against 
susceptible isolates of M tuberculosis supported these regimens since the PAE of 
rifampicin use alone was more than two days (Table 2, 4 & 6) and combined 
regimens including rifampicin would give PAEs around 100 h (Table 6). 
There have been accumulated data on the clinical efficacy of ofloxacin in the 
treatment of tuberculosis with promising results (Todd and Faulds 1991; Willcox 
1993). Major advantages included its excellent oral bioavailability, relative lack of 
drug interactions and the well tolerance of this drug on long term use. In Hong 
Kong, ofloxacin has currently been used as one of the drugs for MDR-TB as well as 
for tuberculosis patients with deranged liver functions in replacement for isoniazid 
(Yew et aL 1992). However, although the dosage used was supported by 
pharmacokinetic data, scheduling of this drug in daily administration was largely 
guess work with little laboratory data to support. Our present study on the PAE and 
KI in vitro and ex vivo showed that ofloxacin gave negligible PAE when used alone 
(Table 2, 4 & 6) with reasonable bactericidal activities (Table 7, 8), but might 
provide a long PAE ex vivo when used in combination with other drugs, especially 
rifampicin and amikacin (Table 6), in addition to the improvement of KI ex vivo 
(Table 8). 
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Levofloxacin, being the active stereoisomer of ofloxacin, possess similar or more 
favourable pharmacokinetic characters to ofloxacin (Une et al 1988; Tanaka et aL 
1990), have been reported to be twice as potent against various organisms including 
M tuberculosis (Klemens et al. 1994; Mor et aL 1994; Saito et al 1995). However, 
our results of PAE and KI in vitro and ex vivo of this dmg used alone did not 
corroborate such findings (Table 2-4, 6-8) and perhaps combined regimens compared 
with ofloxacin should be tested ex vivo followed by careful clinical trials. 
Sparfloxacin has been reported to be the most effective among its class with the 
lowest MICs and MBCs (Rastogi and Goh 1991; Yew et al. 1994) and was thus 
predicted to be of potential in treating MDR isolates that are even resistant to other 
quinolones. Our results again indicated that the PAE and KI were not that 
impressive (Table 2-4, 6-8) and more investigations will be needed as those 
suggested for levofloxacin. 
G. Conclusion & Future Studies 
Results from the present study on PAE and KI in vitro and ex vivo of the six 
antituberculous drugs used alone and in combination among themselves or with other 
drugs against M. tuberculosis isolates have provided laboratory data for the support 
of the clinical antituberculosis chemotherapeutic regimens which have been used to 
treat patients with success. Correlation of PAE with scheduling of the dmg 
administration has strengthened the use of PAE studies for new drugs and new 
regimens which may be designed in the future. The significance of KI should be 
considered if a dmg produces no PAE yet clinical outcome remains successful. 
Future trend of research along this line would include extensive testing of combined 
drugs followed by carefully designed clinical trials. It should be anticipated that 
laboratory findings should provide support to clinical settings and in return the 
clinical outcome may provide rectification of the laboratory research results. 
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